Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Omalizumab in Severe Japanese Cedar Pollinosis
jRCT2080223757Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) comparing Omalizumab with Placebo (2 arms). Started Dec 2017; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on jRCT2080223757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223757.